{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:48Z","timestamp":1779322728223,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:40:39Z","timestamp":1698334839000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-5798","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Mela Osorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Osycka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-3153","authenticated-orcid":false,"given":"Miguel A.","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana In\u00e9s","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-1865","authenticated-orcid":false,"given":"Georgina Emilia","family":"Bendek Del Prete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Fernanda","family":"Tosin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0496-8173","authenticated-orcid":false,"given":"Mariel Ana","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Elisa","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana Ram\u00edrez","family":"Berrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isolda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Sackmann Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Giere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Sighel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10314","key":"10.1016\/j.clml.2023.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clml.2023.10.008_bib0002","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2023.10.008_bib0003","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clml.2023.10.008_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon-2018-0371","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"15","author":"Pavlovsky","year":"2019","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.10.008_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA approval Summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial","volume":"27","author":"Pulte","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2023.10.008_bib0006","unstructured":"National Comprehensive Cancer Network. Chronic myeloid leukemia. Version 1.2024 \u2014 August 1, 2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf (Accessed: October 2023) ."},{"issue":"1","key":"10.1016\/j.clml.2023.10.008_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.clml.2023.10.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia","volume":"10","author":"Molica","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.10.008_bib0009","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2023.10.008_bib0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clml.2023.10.008_bib0011","series-title":"Gu\u00edas De Diagn\u00f3stico y Tratamiento","first-page":"475","article-title":"Leucemia mieloide cr\u00f3nica","author":"Bendek","year":"2021"},{"key":"10.1016\/j.clml.2023.10.008_bib0012","unstructured":"National Cancer Institute. Division of cancer treatment & diagnosis. common terminology criteria for adverse events. v6.0 October 30, 2020. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (Accessed: September 2023)."},{"issue":"7","key":"10.1016\/j.clml.2023.10.008_bib0013","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","article-title":"Real-life experience with ponatinib in chronic myeloid leukemia: a multicenter observational study","volume":"18","author":"Shacham-Abulafia","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.clml.2023.10.008_bib0014","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.008_bib0015","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1182\/blood-2022-166111","article-title":"Last interim results of the real-life study evaluating the efficacy and safety of ponatinib \"Topase\u201d in patients with TKI-resistant or intolerant CML","volume":"140","author":"Cayssials","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2023.10.008_bib0016","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.008_bib0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.clml.2023.10.008_bib0018","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.V124.21.1783.1783","article-title":"Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events","volume":"124","author":"Rivera","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.008_bib0019","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T20:53:08Z","timestamp":1709239988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021523"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}